Isabel Sevilla

Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial

Thierry André, Mayur M. Amonkar, Josephine M. Norquist et al. · The Lancet Oncology · 2021 · 220 citations · Full text

Medicine, Oncology, Chemotherapy +11

Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)

Enrique Grande, Jaume Capdevila, Daniel Castellano et al. · Annals of Oncology · 2015 · 157 citations · Full text

Medicine, Oncology, Pharmacology +13

Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma

Fernando Rivera, Meinolf Karthaus, J. Randolph Hecht et al. · International Journal of Colorectal Disease · 2017 · 142 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)

Jaume Capdevila, Nicola Fazio, Carlos López et al. · Journal of Clinical Oncology · 2021 · 113 citations · Full text

Medicine, Oncology, Pharmacology +16

Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801)

Daniel Castellano, Jaume Capdevila, Javier Sastre et al. · European Journal of Cancer · 2013 · 97 citations

Medicine, Oncology, Pharmacotherapy +13